CHromadex results, advances

• Revenue: $29.1 million in Q4 2024, a 37% increase year-over-year.

• Net Income: $7.2 million in Q4 2024.

• Full Year Revenue: $99.6 million, a 19% growth year-over-year.

• Full Year Net Income: $8.6 million, compared to a net loss of $4.9 million in 2023.

• Cash Flow from Operations: $12.1 million in 2024.

• Cash Balance: $44.7 million with no debt at year-end 2024.

• Gross Margin: Improved by 150 basis points to 62.5% in Q4 2024.

• E-commerce Sales: $17.3 million in Q4 2024, a 30% increase year-over-year.

• NIAGEN Ingredient Sales: $5.3 million in Q4 2024, a 96% increase year-over-year.

• Selling and Marketing Expense: Improved 90 basis points to 29.9% of net sales in Q4 2024.

• General and Administrative Expenses: Decreased by $4.4 million in Q4 2024.

• Operating Income: $7.1 million in Q4 2024, compared to a $200,000 operating loss in Q4 2023.

• For the complete transcript of the earnings call, please refer to the full earnings call transcript.

  Positive Points

  • ChromaDex Corp (NASDAQ:CDXC) reported record revenues of $29.1 million for Q4 2024, marking a 37% increase year-over-year.

  • The company achieved a net income of $7.2 million in Q4 2024, contributing to a full-year net income of $8.6 million, a significant turnaround from a net loss in 2023.

  • ChromaDex Corp (NASDAQ:CDXC) ended the year with $44.7 million in cash and no debt, indicating strong financial health.

  • The e-commerce channel experienced robust growth with net sales of $17.3 million, a 30% increase year-over-year.

  • The NIAGEN ingredients business saw a 96% increase in net sales year-over-year, driven by strong demand for both food-grade and pharmaceutical-grade products.

  Negative Points

  • Supply chain issues delayed the availability of pharmaceutical-grade NIAGEN by two to three months, impacting sales.

  • The company faces challenges from competitors making false claims and infringing on patents, which could affect market share.

  • There is a need for more regulatory action from the FDA and FTC to prevent misleading practices by competitors.

  • General and administrative expenses are expected to increase by approximately $5 million to $6 million in 2025 due to business growth investments.

  • The company anticipates potential impacts from tariffs on international business, although they expect these to be minimal.

  • https://finance.yahoo.com/news/chromadex-corp-cdxc-q4-2024-071005949.html